Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC

1 May 2025

Abstract excerpt

Background Immune evasion is a crucial event in the progression of pancreatic ductal adenocarcinoma (PDAC). The identification of new immunotherapeutic targets may provide a promising platform for advancing PDAC treatment. This study aims to investigate the role of beta-1,4-galactosyltransferase-5 (B4GALT5) in immune evasion by pancreatic cancer cells and evaluate its potential as an immunotherapeutic target....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40316305
DOI: 10.1136/jitc-2024-010908

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDACPMID 40316305Read ↗

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancerSemantic proximity Read ↗

Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapySemantic proximity Read ↗

Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancerSemantic proximity Read ↗

Unraveling the glyco-immunity nexus in pancreatic cancerSemantic proximity Read ↗

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockadeSemantic proximity Read ↗

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read ↗

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor MicroenvironmentSemantic proximity Read ↗

MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.Semantic proximity Read ↗

Mechanism of ASIC4 in Regulating MHC-I-Mediated Immune Evasion in Pancreatic CancerSemantic proximity Read ↗

Identification of a novel immune checkpoint molecule V‐set immunoglobulin domain‐containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.